Search Results
Apr 09, 2026, 07:55 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis. Dr.
More news about: DualityBio
Apr 07, 2026, 11:45 ET Florida Cancer Specialists & Research Institute Phase 3 Trial Demonstrates Initial Clinical Benefit of Novel Immunotherapy For Advanced Non-Small Cell Lung Cancer
note: "The primary endpoint of PRESERVE-003 is overall survival (OS), and secondary endpoints include investigator-assessed progression-free survival (PFS), objective response rate (ORR) and safety."FCS provides ongoing access to more than 180 clinical trials within 29 FCS clinics statewide and early-phase
More news about: Florida Cancer Specialists & Research Institute
Apr 07, 2026, 08:06 ET 27,000 Feet of Drilling, 47 Diamond Holes, and one of the Largest Uranium Deposits in America:
addresses data gaps across resource expansion, classification, metallurgy, rock mechanics, and hydrogeology — some of the building blocks required for a PFS. Drilling is scheduled to commence in early July 2026 using 2-3 rigs over 3-4 months.[1]NexGen Energy (NYSE: NXE) received final CNSC approval
More news about: USA News Group
Apr 07, 2026, 07:00 ET MAYFAIR BOLSTERS EXECUTIVE TEAM WITH ADDITION OF VETERAN CFO
focused on advancing the 100% controlled Fenn-Gib Project in the Timmins region of Northern Ontario. The Project's pre-feasibility study (the "PFS") outlines the potential to develop Fenn-Gib into a new Canadian gold producer for initial development capital of C$450 million, with a base case payback
More news about: Mayfair Gold Corp.
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
21.45 Months):Progression-Free Survival (PFS): In the overall population, median PFS was 7.0 months, with a 6-month PFS rate of 55.7%.Consistent Benefit Across Subgroups: Median PFS was 7.5 months in the squamous NSCLC (sq-NSCLC) subgroup and 7.4 months
More news about: Akeso, Inc.
Apr 02, 2026, 07:00 ET Mayfair Gold Announces Acquisition of the Guibord, Marriott and Holloway Properties from Plato Gold
Canadian gold development stage company focused on advancing the 100% controlled Fenn-Gib Project in the Timmins region of Northern Ontario. The Project's PFS outlines the potential to develop Fenn-Gib into a new Canadian gold producer for initial development capital of C$450 million, with a base case payback
More news about: Mayfair Gold Corp.
Apr 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission, acceptance and outcome of review of the
More news about: ADC Therapeutics SA
Apr 01, 2026, 07:45 ET TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
(FDA). Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated approval process. Key secondary endpoint of Progression Free Survival (PFS) may satisfy the requirement for a post confirmatory trial, converting accelerated approval to regular approval.Initiated
More news about: TuHURA Biosciences, Inc.
Mar 31, 2026, 20:16 ET /C O R R E C T I O N -- U.S. Gold Corp./
entirety, including all qualifications, assumptions, exclusions and risks that relate to the Mineral Resource and Mineral Reserve estimates and the PFS.The Mineral Resource and Mineral Reserve estimates discussed in this news release are classified in accordance with the disclosure requirement
More news about: U.S. Gold Corp.
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
patients treated in the United States (62.4 months) vs. Asia (44.5 months) or Europe (29.6 months).Median overall progression-free survival (PFS) was 13.1 months in the overall measurable disease patient population, but was longer in patients in the United States (25.9 months) vs. Asia (12.6 months)
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 05:40 ET Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
PD-L1–positive non-small cell lung cancer (NSCLC). In the primary analyses of HARMONi-2, ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months compared with 5.82 months for pembrolizumab (HR = 0.51; P < 0.0001), representing a 49% reduction in the risk of disease progression
More news about: Akeso, Inc.
Mar 30, 2026, 17:30 ET Denison Announces Filing of Annual Report on Form 40-F
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ("PFS") was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Mar 30, 2026, 06:00 ET Thesis Gold & Silver Identifies Two Distinct Porphyry Targets on the Lawyers-Ranch Project
porphyry potential identified by the Thesis geology team adds to an already strong project foundation established by the 2025 Prefeasibility Study (the "PFS") (see the news release dated Dec. 1, 2025, entitled "
More news about: Thesis Gold & Silver
Mar 27, 2026, 08:39 ET Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
patients remaining on ZEGFROVY treatment. The estimated 6-month durable response rate was 87.5%.Progression-free survival (PFS) was not mature. The estimated 9-month PFS rate was 83.9%.The safety profile was consistent with previous studies of ZEGFROVY. No new safety signals were observed.Dr. Xiaolin
More news about: Dizal
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
in 1L PD-L1(+) NSCLC, establishing a new "chemo-free" standard. Additionally, the HARMONi-A study marked it as the first immunotherapy to reach dual PFS and OS positivity in EGFR-TKI resistant NSCLC, while HARMONi-6 demonstrated its superiority over tislelizumab (anti-PD-1 monoclonal antibody) in combination
More news about: Akeso, Inc.
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
with a ≥ complete response (≥CR) rate of 76.2%, a minimal residual disease (MRD) negativity rate of 100%, and a 12-month progression-free survival (PFS) rate of 95.2%. The Phase III study was initiated in the second half of 2025.In 2025, we continuously proceeded with a Phase I/II clinical
More news about: Keymed
Mar 25, 2026, 09:02 ET Lifestyle Medicine Whole Person Health Index closes a critical gap in clinical whole-person care
2026 Medicare Physician Fee Schedule (PFS) for physical activity and nutrition assessment and the new
More news about: American College of Lifestyle Medicine
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
3 registrational trial (DYNASTY-Breast01; NCT06265428) and confirmed that the trial had achieved the primary endpoint of Progression-Free Survival ("PFS"), as evaluated by Blinded Independent Central Review ("BICR"), relative to the control arm. This trial is conducted
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 23:30 ET Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
primary analysis. Comparable overall response rates were observed at Week 12, and time-to-event outcomes demonstrated similar progression-free survival (PFS) and overall survival (OS) between treatment groups, with no statistically significant differences identified.HD204 demonstrated a safety and
More news about: Prestige Biopharma
Mar 23, 2026, 22:31 ET KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
Presidential Symposium session at the 2025 ESMO Congress. Sac-TMT achieved statistically significant and clinically meaningful improvements in ORR, PFS, and OS compared to chemotherapy. The study findings were published simultaneously online at the New England Journal of Medicine and in the first
More news about: Kelun-biotech
Mar 23, 2026, 07:00 ET Summit Explore Signs Term Sheet with Power Minerals to Develop Multi-Salar Lithium Project in Argentina
Following execution, Explore would fund development work toward the PFS, including brine testing at Summit's DLE demonstration facility in Santiago. A Technical Committee comprising representatives from both parties will oversee PFS progress, with Explore chairing.All matters contemplated under
More news about: Summit Explore Corporation
Mar 23, 2026, 07:00 ET Summit Explore firma Term Sheet con Power Minerals para desarrollar proyecto de litio multi-salar en Argentina
firma, Explore financiará los trabajos de desarrollo hacia el PFS, incluyendo pruebas de salmuera en la planta de demostración DLE de Summit en Santiago. Un Comité Técnico compuesto por representantes de ambas partes supervisará el avance del PFS, con Explore como presidente del comité.Todas las materias
More news about: Summit Explore Corporation
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
chemotherapy (gemcitabine and nab-paclitaxel).A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.Sickle Cell Disease (SCD) & Gene Therapy
More news about: BioLineRx Ltd.
Mar 21, 2026, 07:26 ET Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted therapyIn addition to improvement in PFS, ZEGFROVY®
More news about: Dizal
Mar 20, 2026, 09:00 ET The Gold Mine That Barrick Bought Into, a Billionaire Backed, and the Market Still Hasn't Found
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Equity Insider